Latest Commercial Execution News

Orthocell has achieved its first commercial sales of Remplir™ in Hong Kong, marking a pivotal step in its Asian growth strategy and expanding its footprint across key global markets.

Immutep has struck a strategic licensing deal with Dr. Reddy’s, granting rights to commercialise its novel cancer immunotherapy Eftilagimod Alfa across key emerging markets. The agreement includes a $20 million upfront payment and potential milestones exceeding $349 million.

New Murchison Gold Limited reports robust November production at Crown Prince Gold Mine, with ore sales exceeding expectations and a $41.6 million payment received from Westgold Resources.

Nexsen Limited has appointed internationally acclaimed surgeon-scientist Professor Shekhar Kumta to its board, aiming to fast-track clinical validation and regulatory approval for its rapid diagnostic platforms ahead of a planned 2026 market entry.

Admiralty Resources has secured a pivotal contract with global trader Trafigura to market its Mariposa Iron Ore, marking a key step towards commercial production and revenue generation.

Orica Limited has delivered its strongest financial performance in over a decade, driven by premium product demand and digital innovation, while advancing ambitious sustainability targets. The company signals continued growth for 2026 despite emerging supply chain challenges.

Orica Limited has reported its strongest earnings in over a decade, with a 23% rise in EBIT to $992 million and a 32% jump in net profit before significant items. The company also increased its share buy-back program and declared a higher dividend, signaling confidence in its growth strategy and sustainability commitments.

The FDA's removal of the black box warning on hormone replacement therapies marks a pivotal shift for Mayne Pharma, potentially unlocking new market opportunities and reshaping women’s health treatment.

AVITA Medical reported a 13% drop in Q3 commercial revenue to $17.1 million but improved its net loss and secured CE Mark approval for RECELL GO in Europe, signaling strategic shifts ahead.

HeraMED has bolstered its cash position with a $1.98 million capital raise and is on the cusp of finalizing two pivotal U.S. commercial agreements, signaling a major step forward for its digital maternity care platform.

Vanadium Resources Limited is advancing its Steelpoortdrift project with fresh leadership, a successful equity raise, and a strategic pivot towards higher-margin concentrate production alongside direct shipping ore.

Memphasys has sharpened its commercial focus on the Felix™ System, securing a major distribution expansion in the MENA region and cutting operational costs by 40%, setting the stage for a global market push.